stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) Operating cash flow
Summit Therapeutics PLC's operating cash flow for fiscal 2025 was −$322.9M, compared with −$142.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$458.4M. Over the past ten years it has ranged from −$322.9M (fiscal 2025) to $16.2M (fiscal 2017) — the current reading is the lowest in ten years. Operating cash flow has fallen for 3 consecutive fiscal years. Summit Therapeutics PLC ranks 589th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$322.9M | — |
| FY2024 | −$142.1M | — |
| FY2023 | −$76.8M | — |
| FY2022 | −$41.6M | — |
| FY2021 | −$72.6M | — |
| FY2020 | −$48.1M | — |
| FY2019 | −$20.8M | — |
| FY2019 | −$35.5M | — |
| FY2018 | −$19.1M | — |
| FY2018 | −$19.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$141.1M | — |
| Mar 2026 | −$122.3M | — |
| Dec 2025 | −$101.9M | — |
| Sep 2025 | −$93.1M | — |
| 45 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.7B |
| HALO Halozyme Therapeutics, Inc. compare | $898.3M |
| BMRN BioMarin Pharmaceutical Inc. compare | $676.6M |
| ASND Ascendis Pharma A/S compare | $404.1M |
| TECH Bio-Techne Corp compare | $292.1M |
| KYMR Kymera Therapeutics, Inc. compare | −$287.6M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.0M |
| SMMT Summit Therapeutics PLC | −$458.4M |
| PCVX Vaxcyte, Inc. compare | −$881.2M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on SMMT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement